Replikins

Andrew Pollack's 4/29
New York Times
article describes the
limitations of existing
vaccine development

	Dr. Sanjay Gupta of CNN discusses the Bogoch Replikins
	ABC Boston on Bogoch Replikins
	BusinessWeek lists Replikins with IBM, NIH, and MIT among other companies with novel Flu-Fighting Tech… Mass High Tech features Replikins, Ltd. in Startup Watch: Five you should follow...
	Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin Peptide Genomic Data Boston, May 23, 2009 Amid all the speculation over what course the Swine Flu epidemic will take, Boston-based biotech firm Replikins Ltd. last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the H1N1 virus will increase markedly, while its lethality will remain relatively low for the immediate future. More
	First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now For Testing Worldwide London, U.K. May 4, 2009 A synthetic peptide H1N1 vaccine is available now for testing worldwide, from Replikins Ltd. The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way (replikins.com). A unique advantage of the Replikins vaccine is its rapid availability; the WHO, CDC and others have stated that conventionally-developed H1N1 vaccines will not be ready for many months. This key advantage is based on the company’s ability to swiftly identify, and make molecular vaccines based on, key sub-sequences of the virus genome that are critical to its rapid replication. In contrast with the decades-old production techniques used for most vaccines, the company also takes full advantage of modern peptide synthesis techniques to allow rapid production of its vaccines. More
	Replikins Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak Boston, April 27, 2009 - See REUTERS coverage Replikins, Ltd. published a FluForecast® warning in April 7th, 2008, a year before the recent Mexico and California H1N1 cases. We were able to state the likelihood of H1N1 outbreaks based on our patented Replikin Count™ genomics technology, which examines specific regions in virus genes which have been linked with past epidemics. The April 2008 announcement, published here and on several sites, stated that in H1N1 we had then detected the highest concentrations of these specific regions ever seen, except for those from the 1918 pandemic which killed tens of millions of people. The original press release can be seen at Medicalnewstoday and Bio-medicine.org Today, we are actively pursuing licensing partnerships to apply our groundbreaking technology not only to early warning systems, but also to the development of synthetic vaccines to prevent or slow future epidemics. A synthetic H1N1 Replikins vaccine is available for testing, and related products are also available and under development. We believe that synthetic vaccines represent the best opportunity to rapidly combat emerging virus threats. We are currently accelerating our development and testing of the synthetic H1N1 vaccine in response to the current outbreak originating in Mexico, and will be announcing further developments at this site over the next few weeks.





	For other FluForecast updates and company announcements, see Replikins Press at left

The current spread of bird flu has drawn attention to the need for improved public health measures to predict, prevent and counter both natural and man-made emerging epidemic threats.

Our FluForecast™ software technology has shown that an increase in Replikin Count™ peptide quantities precedes observed epidemics. In addition, after an epidemic has run its course, there is a decline in Replikin Count™ peptide quantities.

Previously, no quantitative virus protein changes were known which correlate with, let alone predict, influenza epidemics such as the current H5N1 Bird Flu, or indicate their cessation. Advance specific warning, made possible by our discovery of a biochemistry of rapid replication, now allows time a) for public health measures to be instituted, and b) for an early start on synthetic vaccine development.


		Recent outbreaks of SARS, H5N1 (bird flu) and H1N1 (swine flu) have increased awareness of the need for rapid vaccine development in response to emerging viral threats. Replikins software-driven technology allows for earlier development of vaccine candidates, as well as rapid prototyping and production of the vaccines that emerge from early clinical trials. Replikins are a new class of peptides whose increase in concentration in virus proteins (Replikin Count™ peptide quantities) is associated with rapid replication. Subtypes of these peptides are consistently present in a wide range of rapidly-replicating viruses, pointing the way towards synthesis of vaccine candidates.